期刊文献+

高敏C反应蛋白与易损斑块相关性的iMAP-血管内超声研究 被引量:8

Assessment for the Relationship Between hs-CRP and Vulnerable Plaques in Patients With Acute Coronary Syndrome by Intravascular Ultrasound
下载PDF
导出
摘要 目的:通过iMAP-血管内超声(iMAP—IVUS)分析动脉粥样硬化斑块成分,探讨高敏C反应蛋白(hs—CRP)与易损斑块问的相关性。方法:连续筛选于我院心内科住院治疗,需接受择期冠状动脉(冠脉)造影(CAG)或经皮冠脉支架置入术并完成血管内超声(IVUS)的急性冠脉综合征(ACS)患者189例,所有患者于入院时检测hs—CRP,根据hs—CRP水平将患者分为两组:低水平组:hs—CRP≤3mg/L;高水平组:hs—CRP〉3mg/L,分析两组患者CAG及IVUS影像学结果。结果:①与低水平组患者相比,高水平组患者有更高的白细胞、肌酐、肌酸激酶MB同工酶(CK—MB)及B型利钠肽(BNP)水平(P〈0.05),其hs—CRP及超敏肌钙蛋白(cTnI)显著高于低水平组(P〈0.01)。②高水平组患者病变含有较少的钙化成分(P=O.002)、更多的坏死核心(P〈0.001)及更高的薄纤维帽斑块(TCFA)发生率(P=O.003)。③hs—CRP是TCFA的独立预测因子(比值比:2.457,95%CI:1.34~4.49,P=0.003)。结论:经iMAP~血管内超声证实,hs—CRP与ACS患者易损斑块有良好的相关性,可作为预测易损斑块的炎性标志物。 Objective: To assess the relationship between high sensitivity C-reactive protein (hs-CRP) and vulnerable plaques in patients with acute coronary syndrome (ACS) by intravascular ultrasound (IVUS). Methods: A total of 189 ACS patients who received elective CAG, PCI and 1VUS in our hospital were analyzed. The hs-CRP level was examined at admission and the patients were divided into 2 groups. Low hs-CRP (43 mg/L) group, n=117 and High hs-CRP (〉3 mg/L) group, n=72. The CAG, IVUS imaging and hs-CRP levels were compared between 2 groups. Results: Compared with Low hs-CRP group, the High hs-CRP group presented significantly increased WBC, serum creatinine, creatine kinase MB (CK-MB), BNP and cardiac troponin I (cTnl), all P〈0.05. The plaques in High hs-CRP group had less calcification (P=0.002), more necrosis in the core (P〈0.001) and more frequency of thin-cap fibroatheroma (TCFA) (P=0.003). hs-CRP was an independent predictor of TCFA (OR=2.457, 95% CI 1.34-4.49, P=0.003). Conclusion: IVUS indicated that hs-CRP is obviously related to vulnerable plaque component in ACS patients and it could be used as the inflammatory biomarker for vulnerable plaques.
出处 《中国循环杂志》 CSCD 北大核心 2014年第4期252-255,共4页 Chinese Circulation Journal
基金 天津市卫生局课题(2010KZ63)
关键词 高敏C反应蛋白 易损斑块 血管内超声 High sensitivity C-reactive protein Vulnerable plaques Intravascular ultrasound
  • 相关文献

参考文献4

二级参考文献36

  • 1李小鹰.阿司匹林在动脉硬化性心血管疾病中的临床应用:中国专家共识(2005)[J].中华心血管病杂志,2006,34(3):281-284. 被引量:194
  • 2Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction-summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines(Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol,2002, 40(7) :1366-1374.
  • 3Bertrand ME, Simoons ML, Fox KA, et al. Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J,2002,23 ( 23 ) : 1809 -1840.
  • 4Erhardt L, Herlitz J, Bossaert L, et al. Task force on the management of chest pain. Eur Heart J, 2002, 23 ( 15 ) : 1153-1176.
  • 5CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet, 1996, 348(9038) :1329-1339.
  • 6Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med, 2001 , 345 ( 7 ) :494-502.
  • 7Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet, 2001, 358(9281):527-533.
  • 8Simoons ML, GUSTO IV-ACS Investigators. Effect of glycopmtein Ⅱb/Ⅲa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation:the GUSTO IV-ACS randomised trial. Lancet, 2001,357(9272) :1915-1924.
  • 9Platlat Receptor Inhibitor in Ischemic Syndrome Management(PRISM) study investigator. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. Platelet Receptor Inhibition in Ischemic Syndrome Management ( PRISM )Study Investigators. N Engl J Med, 1998, 338(21 ) :1498-1505.
  • 10Platlat Receptor Inhibitor in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms(PRISM-PLUS) study investigator. Inhibition of the platelet giycoprotein Ⅱb/Ⅲa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. N Engl J Med,1998, 338(21) :1488-1497.

共引文献2211

同被引文献55

引证文献8

二级引证文献66

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部